Hepatitis B medical therapy


 * Associate Editor In Chief: ;

Treatment
In the first few months of infection, hepatitis B does not usually get treated. Up to 95% of adults clear the infection spontaneously without treatment. Therapy in this stage of infection does not seem to further improve the chances of spontaneous cure. Early antiviral treatment may only be required in fewer than 1% of patients, whose hepatitis B takes a very aggressive course ("fulminant hepatitis").

There are currently several treatments for chronic hepatitis B. While none of the available drugs usually clear the infection, they can stop the virus from replicating, and prevent liver damage such as cirrhosis and/or liver cancer. Treatments are available in the form of antiviral drugs such as lamivudine, adefovir, entecavir or telbivudine, and immune system modulators such as interferon alpha (Uniferon) or peg-interferon alpha (PEGASYS). There are several other antivirals under investigation. However, some individuals are much more likely to respond than others. It does not appear that combination therapy offers any advantages, but may help in patients with resistant viruses, or in advanced liver disease where resistant viruses may lead to liver failure. In general, each treatment works by reducing the viral load by several orders of magnitude. In some patients, chronic hepatitis B takes a mild course and does not require immediate treatment. Treatment strategies should be individualized. Considerations include a person's risk for developing complications of persistent infection, a person's likelihood of adhering and responding to treatment, and potential risks such as side effects or development of viral resistance.

On March 29, 2005, the US Food and Drug Administration (FDA) approved Entecavir for the treatment of hepatitis B.

On February 25, 2005, the EU Commission approved PEGASYS for the treatment of hepatitis B making it the first pegylated interferon to be approved for hepatitis B.

On October 27, 2006, telbivudine gained FDA approval for treatment of chronic hepatitis B. It is marketed under the brand name Tyzeka in the US and Sebivo outside the US. It is already approved in Switzerland.

Chronic carriers are encouraged to avoid consuming alcohol as it increases their risk for cirrhosis and hepatocellular carcinoma (liver cancer).

Infants born to mothers known to carry hepatitis B can be treated with antibodies to the hepatitis B virus (hepatitis B immune globulin or HBIg). When given with the vaccine within twelve hours of birth, the risk of acquiring hepatitis B is reduced 95%. This treatment also allows a mother to safely breastfeed her child.

An individual exposed to the virus who has never been vaccinated may be treated with HBIg immediately following the exposure. For instance, a health care worker accidentally stuck by a needle used in a hepatitis B carrier would qualify. Treatment must be soon after exposure, however.

As a summary:

There are no medications available for recently acquired (acute) HBV infection. Hepatitis B vaccine is available for the prevention of HBV infection. There are antiviral drugs available for the treatment of chronic HBV infection.


 * HBV infected persons should be evaluated by their doctor for liver disease.
 * Adefovir dipivoxil, interferon alfa-2b, pegylated interferon alfa-2a, lamivudine, entecavir, and telbivudine are six drugs used for the treatment of persons with chronic hepatitis B.
 * These drugs should not be used by pregnant women.
 * Drinking alcohol can make liver disease worse.

==Recommendations on Whom to Treat and with What Antiviral Agent: AASLD Practice Guidelines 2009 == 1. Patients with HBeAg-positive chronic hepatitis B
 * a. ALT greater than 2 times normal or moderate/severe hepatitis on biopsy, and HBV DNA >20,000 IU/mL. These patients should be considered for treatment. (Grade I)
 * Treatment should be delayed for 3 to 6 months in persons with compensated liver disease to determine if spontaneous HBeAg seroconversion occurs. (Grade II-2)
 * Patients with icteric ALT ﬂares should be promptly treated. (Grade III)
 * Treatment may be initiated with any of the 7 approved antiviral medications, but pegIFN-α, tenofovir or entecavir are preferred. (Grade I)
 * b. ALT persistently normal or minimally elevated (<2 times normal). These patients generally should not be initiated on treatment. (Grade I)
 * Liver biopsy may be considered in patients with ﬂuctuating or minimally elevated ALT levels especially in those above 40 years of age. (Grade II-3)
 * Treatment may be initiated if there is moderate or severe necroinﬂammation or signiﬁcant ﬁbrosis on liver biopsy. (Grade I)
 * c. Children with elevated ALT greater than 2 times normal. These patients should be considered for treatment if ALT levels remain elevated at this level for longer than 6 months. (Grade I)
 * Treatment may be initiated with IFN-α or lamivudine. (Grade I)

2. Patients with HBeAg-negative chronic hepatitis B (serum HBV DNA >20,000 IU/mL and elevated ALT >2 times normal) should be considered for treatment. (Grade I)
 * Liver biopsy may be considered for HBeAg-negative patients with lower HBV DNA levels (2,000-20,000 IU/mL) and borderline normal or minimally elevated ALT levels. (Grade II-2)
 * Treatment may be initiated if there is moderate/severe inﬂammation or signiﬁcant ﬁbrosis on biopsy. (Grade I)
 * Treatment may be initiated with any of the 7 approved antiviral medications but pegIFN-α, tenofovir or entecavir are preferred in view of the need for long-term treatment. (Grade I for pegIFN-α, tenofovir, or entecavir and Grade II-1 for IFN-α, adefovir, telbivudine and lamivudine).

3. Patients who failed to respond to prior IFN-α (standard or pegylated) therapy may be retreated with nucleoside analogues (NA) if they fulﬁll the criteria listed above. (Grade I)

4. Patients who failed to achieve primary response as evidenced by <2 log decrease in serum HBV DNA level after at least 6 months of NA therapy should be switched to an alternative treatment or receive additional treatment. (Grade III)

5. Patients who develop breakthrough infection while receiving NA therapy
 * Compliance should be ascertained, and treatment resumed in patients who have had long lapses in medications. (Grade III)
 * A conﬁrmatory test for antiviral-resistant mutation should be performed if possible to differentiate primary nonresponse from breakthrough infection and to determine if there is evidence of multi-drug resistance (in patients who have been exposed to more than one NA treatment). (Grade III)
 * All patients with virologic breakthrough should be considered for rescue therapy. (Grade II-2)
 * For patients in whom there was no clear indication for hepatitis B treatment and who continue to have compensated liver disease, withdrawal of therapy may be considered but these patients need to be closely monitored and treatment reinitiated if they experience severe hepatitis ﬂares. (Grade III)

6. Treatment of patients with lamivudine (or telbivudine)-resistant HBV
 * a. If adefovir is used, lamivudine (or telbivudine) should be continued indeﬁnitely to decrease the risk of hepatitis ﬂares during the transition period and to reduce the risk of subsequent adefovir resistance. (Grade II-3 for lamivudine-resistant HBV and III for telbivudineresistant HBV)
 * b. If tenofovir is used, continuation of lamivudine (or telbivudine) is recommended to decrease the risk of subsequent antiviral resistence. (Grade III)
 * c. If entecavir is used, lamivudine or telbivudine

should be stopped as continued presence of lamivudine- (or telbivudine-) resistant mutations will increase the risk of entecavir resistance. (Grade II-3 for lamivudine-resistant HBV and Grade III for telbivudine-resistant HBV). Entecavir is not an optimal therapy because of increasing risk of resistance to entecavir over time. (Grade II-2)

7. Treatment of patients with adefovir-resistant HBV
 * a. In patients with no prior exposure to other NA, lamivudine, telbivudine or entecavir may be added. Alternatively, adefovir may be stopped and tenofovir plus lamivudine or emtricitabine may be used. (Grade III)
 * b. In patients with prior lamivudine resistance in whom lamivudine had been stopped when treatment was switched to adefovir, adefovir may be stopped and tenofovir plus lamivudine, emtricitabine (Grade II-2) or entecavir (Grade III) may be used but the durability of response to this combination is unknown.

8. Treatment of patients with entecavir-resistant HBV
 * a. Adefovir or Tenofovir can be used as it has been shown to have activity against entecavir-resistant HBV in in vitro studies, but clinical data are lacking. (Grade II-3)

9. Patients with compensated cirrhosis — Treatment should be considered for patients with ALT >2 times normal, and for patients with normal or minimally elevated ALT if serum HBV DNA levels are high (>2,000 IU/mL). (Grade II-2)
 * a. Patients with compensated cirrhosis are best treated with NAs because of the risk of hepatic decompensation associated with IFN-α–related ﬂares of hepatitis. In view of the need for long-term therapy, tenofovir or entecavir is preferred. (Grade II-3)

10. Patients with decompensated cirrhosis — Treatment should be promptly initiated with a NA that can produce rapid viral suppression with low risk of drug resistance. (Grade II-1)
 * a. Lamivudine or telbivudine may be used as initial treatment in combination with adefovir or tenofovir to reduce the risk of drug resistance. (Grade II-2)
 * b. Entecavir or tenofovir alone would be an appropriate treatment in this setting but clinical data documenting their safety and efﬁcacy in patients with decompensated cirrhosis are lacking. (Grade III)
 * c. Treatment should be coordinated with a transplant center. (Grade III)
 * d. IFN-α/pegIFN-α should not be used in patients with decompensated cirrhosis. (Grade II-3)

11. In patients with inactive HBsAg carrier state antiviral treatment is not indicated, but these patients should be monitored.

==Recommendations for Dose Regimens: AASLD Practice Guidelines 2009 == 1. IFN-α and pegIFN-α are administered as subcutaneous injections.
 * a. The recommended dose of standard IFN-α for adults is 5 MU daily or 10 MU thrice weekly. The recommended dose of pegIFN-α2a is 180 mcg weekly. (Grade I)
 * b. The recommended IFN-α dose for children is 6 MU/m2 thrice weekly with a maximum of 10 MU. (Grade I). PegIFN-α has not been approved for treatment of chronic hepatitis B in children.
 * c. The recommended treatment duration for HBeAg-positive chronic hepatitis B is 16 weeks for standard IFN-α and 48 weeks for pegIFN-α. (Grade I)
 * d. The recommended treatment duration for HBeAg-negative chronic hepatitis B is 48 weeks for both standard and pegIFN-α (Grade II-3).

2. Lamivudine is administered orally.
 * a. The recommended lamivudine dose for adults with normal renal function and no HIV coinfection is 100 mg daily (Grade I). Dose adjustment is needed for patients with estimated glomerular ﬁltration rate <50 mL/min. (Grade I)
 * b. The recommended lamivudine dose for children is 3 mg/kg/d with a maximum of 100 mg/d. (Grade I)
 * c. The recommended dose of lamivudine for persons coinfected with HIV is 150mg twice daily. Lamivudine should only be used in combination with other antiretroviral medications. (Grade I)

3. Adefovir is administered orally.
 * a. The recommended adefovir dose for adults with normal renal function is 10 mg daily. (I) Dose adjustment is needed for patients with estimated glomerular ﬁltration rate <50 mL/min.

4. Entecavir is administered orally.
 * a. The recommended entecavir dose for adults with normal renal function is 0.5 mg daily for patients with no prior lamivudine treatment, and 1.0 mg daily for patients who are refractory/resistant to lamivudine. (Grade I). Dose adjustment is needed for patients with estimated glomerular ﬁltration rate <50 mL/min.

5. Telbivudine is administered orally.
 * a. The recommended dose for adults with normal renal function is 600 mg daily. (Grade I) Dose adjustment is needed for patients with estimated glomerular ﬁltration rate <50 mL/min.

6. Tenofovir is administered orally.
 * a. The recommended tenofovir dose for adults with normal renal function is 300 mg daily. (Grade I) Dose adjustment is needed for patients with estimated creatinine clearance <50 mL/min.

7. Duration of nucleoside analogue treatment
 * a. HBeAg-positive chronic hepatitis B — Treatment should be continued until the patient has achieved HBeAg seroconversion and undetectable serum HBV DNA and completed at least 6 months of additional treatment after appearance of anti-HBe. (Grade I)
 * Close monitoring for relapse is needed after withdrawal of treatment. (Grade I)
 * b. HBeAg-negative chronic hepatitis B — Treatment should be continued until the patient has achieved HBsAg clearance. (Grade I)
 * c. Compensated cirrhosis — These patients should receive long-term treatment. However, treatment may be stopped in HBeAg-positive patients if they have conﬁrmed HBeAg seroconversion and have completed at least 6 months of consolidation therapy and in HBeAg-negative patients if they have conﬁrmed HBsAg clearance. (Grade II-3)
 * Close monitoring for viral relapse and hepatitis ﬂare is mandatory if treatment is stopped. (Grade II-3)
 * d. Decompensated cirrhosis and recurrent hepatitis B post–liver transplantation — Life-long treatment is recommended. (Grade II-3)

==Recommendations for Initial Evaluation of Persons with Chronic HBV Infection: AASLD Practice Guidelines 2009 == 1. Initial evaluation of persons newly diagnosed with chronic HBV infection should include history, physical examination and laboratory testing. (Grade III)

2. All persons with chronic hepatitis B not immune to hepatitis A should receive 2 doses of hepatitis A vaccine 6 to 18 months apart. (Grade II-3)

==Recommendations for Treatment of Patients with Acute Symptomatic Hepatitis B: AASLD Practice Guidelines 2009 == 1. Treatment is only indicated for patients with fulminant hepatitis B and those with protracted, severe acute hepatitis B. (Grade III)

2. Lamivudine or telbivudine may be used when the anticipated duration of treatment is short; otherwise, entecavir is preferred. (Grade II-3)
 * a. Treatment should be continued until HBsAg clearance is conﬁrmed or indeﬁnitely in those who undergo liver transplantation. (Grade II-1)
 * b. IFN-α is contraindicated. (Grade III)